IGF-1 LR3

Batch #327653Batch #327653
Report #53449Report #53449
Tested at 99.51% purityTested at 99.51% purity
Size: 1mg
Visa Mastercard American Express Discover Apple Pay Google Pay
Ships by ...
Flag
FREE Shipping

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About IGF-1 LR3

IGF-1 LR3 (insulin-like growth factor-1 long arginine 3) is a synthetic variant of insulin-like growth factor-1. Its reduced binding to IGF-1 binding proteins allows it to remain active up to 120 times longer than standard IGF-1 resulting in an extended half-life and increased efficacy. IGF-1 LR3 has been investigated for its potential role in tissue repair and cellular growth.

Product Specifications

IGF-1 LR3 Lyophilized Powder in 3ml vial.

Application

Research peptide Insulin-like Growth Factor-1 Long R3

Appearance

Solid, white powder in 2mL glass ampule

Chemical Formula

C400H625N111O115S9

PubChem CID
CAS Number

946870-92-4

Molecular Weight

~9,117.5 g/mol

Synonyms

Insulin-like Growth Factor-1 Long R3, Long R3 IGF-1

Storage

Store at ≤4°C, sealed, away from heat, light, and moisture.

IGF-1 LR3 Research

1) Clinical Overview

IGF-1 LR3 (Long R3 IGF-1) is a bioengineered analog of human IGF-1 that retains the full IGF-1 sequence with a Glu→Arg substitution at position 3 and a 13-amino-acid N-terminal extension. These changes markedly reduce affinity for IGF-binding proteins (IGFBPs), increasing bioavailability at the IGF-1 receptor (IGF1R) and enhancing potency in vitro. LR3 is widely used as a cell-culture supplement to promote survival and productivity at concentrations far lower than insulin or native IGF-1; it is not approved for therapeutic use in humans. 

2) Human Clinical Findings

Controlled human trials of IGF-1 LR3 specifically are not available in the published literature; most clinical data involve native recombinant human IGF-1 (mecasermin), which is FDA-approved for severe primary IGF-1 deficiency in children and has its own risk profile. Trials of native IGF-1 for other indications (e.g., ALS) have not shown clear benefit. Accordingly, LR3’s human efficacy and safety remain unestablished. 

(For context only) Selected non-human studies show mixed physiological effects: continuous LR3 infusion in pigs reduced growth rate and suppressed endogenous GH/IGF-axis hormones, and LR3 has been used to modulate protein metabolism in livestock models. Species responses vary and should not be extrapolated to humans. 

3) Mechanism & Effects

Receptor activation and IGFBP evasion. IGF-1 LR3 activates IGF1R to drive downstream PI3K–Akt and MAPK signaling (myogenic, metabolic, survival pathways). Its engineered sequence confers much lower IGFBP affinity, increasing the fraction of free ligand available to bind IGF1R compared with native IGF-1. Comparative binding/structure papers and IGF system reviews detail these features and the central regulatory role of IGFBPs. 

In vitro potency / bioprocess use. In mammalian cell culture (CHO, HEK293), LR3 supports cell growth and viability and can replace high-dose insulin at 100- to 200-fold lower concentrations, improving recombinant protein yields in serum-free media. 

Physiology in animals. In vivo effects depend on species, dose, and exposure pattern. For example, LR3 reduced feed intake and growth in pigs while suppressing circulating IGF-1, IGFBP-3, insulin and GH, highlighting feedback within the GH/IGF axis. 

4) Safety & Considerations

Regulatory status. IGF-1 LR3 is not an approved drug for humans; products marketed online are unregulated. By contrast, mecasermin (rhIGF-1) is approved for specific pediatric indications and carries labeled risks. 

What we can infer (from rhIGF-1, not LR3). With approved rhIGF-1 therapy, the most frequent adverse reactions are hypoglycemia, tonsillar hypertrophy, and hypersensitivity; intracranial hypertension has been reported. These data do not establish LR3’s human safety, but they illustrate class risks tied to potent IGF-1 signaling. 

Sport / anti-doping. IGF-1 and its analogues are prohibited at all times under the WADA S2 class (Peptide hormones, growth factors, related substances). 

References 

  1. Laajoki LG, et al. Solution structure and backbone dynamics of long-[Arg(3)]IGF-I. Eur J Biochem. 2000. (Defines Arg3 substitution + N-terminal extension). 
  2. Yang Y, et al. Probing the Folding Pathways of Long R3 IGF-1. J Biol Chem. 1999. (Structural features of LR3). 
  3. Voorhamme D, et al. LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Mol Biotechnol. 2006. (Cell-culture potency). 
  4. Dahodwala H, et al. CHO cells producing monoclonal antibodies… Biotechnol Prog. 2011. (LR3 improves growth/productivity in CHO).
  5. Forbes BE, et al. Characteristics of binding of IGF peptides and analogues to IGF1R. FEBS Lett. 2002. (Receptor binding comparisons).
  6. Clemmons DR. 40 Years of IGF-1: Role of IGF-binding proteins in IGF-1 physiology. J Mol Endocrinol. 2018. (IGFBP biology). 
  7. Dunaiski V, et al. Long [R3] IGF-I reduces growth and alters GH/IGF axis in pigs. J Endocrinol. 1998. (In vivo pig study). 
  8. Regulatory/label context (native rhIGF-1): INCRELEX® (mecasermin) prescribing information; Fintini D. Ther Clin Risk Manag. 2009 review; FDA ALS docket summarizing IGF-1 trials. 
  9. Anti-doping: World Anti-Doping Agency. 2025 Prohibited List. S2 (IGF-1 and analogues). 

 

You ask,
we answer.